NTx Taps Biopharma Industry Executive Nancy Rurkowski to Join its Board of Directors

The 35-year veteran of Bristol-Myers Squibb brings manufacturing operations and product launch leadership expertise to drive NTx commercialization efforts

(Photo: Business Wire)

RIO RANCHO, N.M.--()--NTx, biomanufacturing and bioinformatics company, today announced that biopharma industry veteran Nancy Rurkowski has joined its Board of Directors.

Rurkowski brings over 35 years of pharmaceutical and biologics operations experience from Bristol-Myers Squibb. Over the course of her career, she held global leadership roles across strategic sourcing, new product launch, global supply chain, process development, quality, and manufacturing operations.

During the last decade of her career at Bristol-Myers Squibb, Rurkowski moved back into executive roles in pharmaceuticals and worked closely with research and development and commercial teams to launch new products. She led a biologics manufacturing site for clinical and commercial supply of drug substance and was also responsible for worldwide quality for the biologics drug substance manufacturing network.

“NTx has developed a number of technology platforms that have enabled step changes in the discovery, development and manufacture of vaccines and biologics,” said Nancy Rurkowski. “Over the course of my career, I have served as a bridge between scientists and plant engineers to realize the potential of technology and I am excited to share this experience to help NTx drive market adoption.”

Rurkowski joins a Board of Directors comprised of distinguished pharmaceutical and biotechnology leaders, including Andrew Weber, former U.S. Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense; Charles McMillan, former director of the Los Alamos National Laboratory; Joseph Sullivan, Chief Operations Officer at NTx; David Seldin, Managing Partner at Anzu Partners; Thomas Nickoloff, Managing Principal at Camino Real Capital Partners; NTx co-founder and CTO, Dr. Michael Humbert; and NTx co-founder, CEO and CSO, Dr. Alex Koglin.

“We are thrilled to have Nancy join the NTx team as the company continues to grow and gain commercial traction,” said Dr. Alex Koglin, co-founder, CEO and CSO of NTx. “Her expertise across manufacturing, supply chain, technical operations and more, will be invaluable as we move into our new facility and ramp capacity.”

For more information about NTx and its proprietary platform, please visit: https://www.ntxbio.com.

About NTx

NTx is a bioinformatics and biomanufacturing company that advances medical products and material sciences with cell-free, innovative biomanufacturing solutions. The company is commercializing its biomanufacturing systems NTxpress®, NTxscribe® and the bioinformatics platform, DruID, for the discovery of natural products. NTx biosynthesis technology, which is built for mRNA and proteins that are made in-vitro, is completely defined as it is not dependent on cell lines. Its biomanufacturing processes can easily be scaled to meet fluctuating supply needs so that companies can increase and streamline production as they respond to changing global demands. For more information, please visit: https://www.ntxbio.com.


Kalyn Schieffer, kos@anzupartners.com

Release Summary

Biopharma industry veteran Nancy Rurkowski has joined the NTx Board of Directors with over 35 years of experience from Bristol-Myers Squibb.


Kalyn Schieffer, kos@anzupartners.com